At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
One shared journey is moving us forward at Bristol-Myers Squibb. Around the world, we are a passionate industry leading organization committed to making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents, ideas, and integrity to collaborate and swiftly deliver operational excellence and high-quality data. We are driven to make a difference, from cutting edge research, to hands-on community support. Bristol-Myers Squibb recognizes the importance of balance and flexibility, and values diversity and inclusion in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees opportunities for growth, both at work and in their personal lives.
Description: The Global Trial Manager (Non-Registrational Trials) is a diverse, challenging, and central leadership role within Global Clinical Operations working in a dynamic matrix project team. This role drives the successful and timely execution of Non-Registrational clinical research protocols (e.g. Non-Interventional Studies, Registries, Health Economic Outcomes Research, etc.) from study start-up to final clinical study report within established budget and timelines using strong project management and organizational skills. This role monitors protocol progress and addresses and manages obstacles, serves as the primary operational contact for the protocol at BMS who works closely with the CRO, coordinates the development of protocol level documents and plans, and effectively leads a multifunctional BMS team while collaborating with the CRO and other external stakeholders. This role ensures effective management of issues and risks, and concise escalation and reporting to BMS and CRO management, appropriate teams and collaborating functions. This individual also must leverage her/his strong interpersonal and influencing skills and proven team-building skills, to foster partnerships across projects and multidisciplinary teams. Other activities may include but are not limited to overseeing and/or support of the following: CRO selection process; preparation of the CRO contract and specifications; site identification; vendor selection; preparation, negotiations and approval of site agreements.
Requirements: A minimum of a BA or BS Degree with 4 to 6 years of demonstrated project management experience of which at least 2 should have been gained in the pharmaceutical or healthcare industry. Experience working in Non-Registrational Research (e.g. Non-Interventional Studies, Registries, Health Economic Outcomes Research, etc.) is strongly preferred. This candidate should demonstrate strong project management and organizational skills and the following skills and knowledge:
* Disease / therapeutic knowledge Excellent oral / written / presentation communications skills
* Expert knowledge of regulatory requirements in the US, and additional countries per study requirements
* Leadership skills / negotiation skills
* Mentoring / coaching
* Time management - ability to effectively multi-task and prioritize
* Financial budgeting and forecasting skills
* Expert project management / organizational skills
* Solid computer skills requirement of MS applications including (but not limited to) MS Project, Word, Excel
* Study Tools including electronic system skills EDC
LOCATION - please note - Candidates that live within a 50 mile radius of a BMS office will be required to work at a BMS office location. Candidates in US that live over a 50 mile radius will be provided the opportunity to work remotely.
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Our company is committed to ensuring that people with disabilities can excel through a transparent recruitment process, reasonable workplace adjustments and ongoing support in their roles. Applicants can request an approval of accommodation prior to accepting a job offer. If you require reasonable accommodation in completing this application, or any part of the recruitment process direct your inquiries to adastaffingsupport@bms.com. Visit careers.bms.com/eeo-accessibility to access our complete Equal Employment Opportunity statement.
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.